AC Immune SA Announces Amendment to Collaboration with Lilly
AC Immune SA, a clinical-stage biopharmaceutical company, announced on April 7, 2026, an amendment to its 2018 license and collaboration agreement with Eli Lilly and Company to research and develop Tau aggregation inhibitor small molecules for Alzheimer’s disease and other neurodegenerative diseases, according to GlobeNewswire PE. The amendment continues the research collaboration to cover development of new lead Tau Morphomer candidates and potential back-up compounds.
Details of the Amendment
Under the amendment, AC Immune will focus on advancing Tau Morphomer candidates that can enter the brain when dosed orally and specifically bind to the pathological conformation of the Tau protein. AC Immune has generated preclinical data indicating that these candidates could inhibit Tau aggregation and seeding across disease stages. Dr. Andrea Pfeifer, CEO of AC Immune SA, stated that the collaboration highlights breakthroughs in Morphomer small molecules for intracellular Tau targeting.
Financial Aspects of the Deal
AC Immune will receive a CHF10 million upfront payment and a subsequent milestone payment upon Phase 1 dosing, in addition to milestones from a prior amendment. The company is eligible for further development, regulatory, and commercial milestones totaling over CHF1.7 billion, plus tiered royalty payments in the low double digits, as previously disclosed. This structure builds on AC Immune’s history of securing strategic partnerships with global pharmaceutical companies.
About AC Immune and Its Focus
AC Immune SA is a clinical-stage biopharmaceutical company that pioneers precision therapeutics for neurodegenerative diseases using its SupraAntigen and Morphomer technology platforms. The company has a pipeline featuring therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development for conditions driven by misfolded proteins, according to GlobeNewswire PE. As widely-known context, neurodegenerative diseases like Alzheimer’s affect millions globally and represent a major focus for biopharmaceutical innovation, though specific outcomes remain uncertain.
